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Background: Using a genome-wide approach, we have previously observed an increase in the frequency of rare
copy number variants (CNVs) in familial and early-onset breast cancer cases when compared to controls. Moreover,
the biological networks of the CNV disrupted genes differed between the two groups. Here, six of the previously
observed CNVs were selected for further investigation. Four of these were singletons and disturbed the following
genes: DCLRE1C, CASP3, DAB2IP and ITGA9, encoding proteins that are part of the TP53 and β-estradiol centered
network. The two others were recurrent alleles and disrupted CDH19 and CYP2C19 genes. Of these, CDH19 encodes
a cadherin functioning as a cell-cell adhesion receptor and CYP2C19 a CYP450 enzyme with a major function in
estrogen catabolism.
Methods: The exact breakpoints of the six previously observed CNV deletion alleles were defined by using qPCR,
nested PCR and sequencing. The prevalence of these CNVs was investigated in 842 Northern Finnish breast cancer
cases, unselected for family history of cancer and age at disease onset, as well as in 497 healthy female controls by
using multiplex PCR. Also the association of the relatively common CDH19 and CYP2C19 deletion alleles with
different clinical parameters was studied.
Results: No significant differences in the carrier frequencies between cases and controls were found for any of the
studied CNVs. However, the deletion in CYP2C19 showed a significant association with triple-negative breast cancer
(p = 0.021).
Conclusion: Our results indicate that inherited changes in CYP2C19 gene participating in estrogen catabolism have
an influence on the molecular subtype of breast cancer.
Keywords: Copy number variation, CYP2C19, Triple-negative breast cancerBackground
Copy number variants (CNVs) are genomic microdupli-
cations or microdeletions which can affect gene function
and predispose to various diseases [1], including breast
cancer. Although no evidence for the association of com-
mon CNVs with breast cancer susceptibility has been re-
ported [2], recent genome-wide studies suggest that rare
CNVs represent an alternative source of genetic variation
influencing hereditary breast cancer risk [3,4]. In our
previous study, we observed a consistent increase in the* Correspondence: robert.winqvist@oulu.fi; katri.pylkas@oulu.fi
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article, unless otherwise stated.frequency of rare CNVs in familial and early-onset breast
cancer cases when compared to controls. Furthermore,
the biological networks of the disrupted genes differed
between the two groups: the disrupted genes in breast
cancer cases were shown to be closely related to estro-
gen signalling and TP53 centered tumor suppressor
network [4].
Based on their biological functions and recurrence, two
of the previously identified deletion alleles disrupting
CYP2C19 and CDH19 genes, respectively, were hypothe-
sized to play a role in breast cancer predisposition also in
the general population. Of these, CYP2C19 encodes a
CYP450 enzyme with a major function in estrogen catab-
olism: it catalyzes 17 β-hydroxy dehydrogenation and 16
α-hydroxylation of estradiol [5,6]. CYP2C19 has also been
reported to participate in tamoxifen metabolism duringtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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hydroxylation [7]. The decreased activity of CYP2C19
through haploinsufficiency might be related to an increase
in breast cancer risk, potentially through life-long in-
creased estrogen levels [4]. In contrast, CDH19 encodes a
cadherin, which is a cell-cell adhesion receptor establish-
ing and maintaining intercellular connections. Loss of
function of cadherins may be connected to cancer forma-
tion [8]. In our previous study, the CYP2C19 deletion al-
lele was found twice as frequent in familial breast cancer
cases (5.8%) as in controls (2.3%), whereas CDH19 was
observed once in both familial (1.0%) and control cohorts
(0.8%) [4], implicating the need for a larger dataset for the
evaluation of their disease relatedness. Besides the breast
cancer risk itself, both changes could also have an effect
on tumor biology.
Although a majority of the previously observed CNV al-
leles, which disrupted genes from the TP53 and β-estradiol
centered network, were singletons [4], some could repre-
sent founder mutations typical for the Finnish population.
Thus, based on their biological functions, four singleton
deletion alleles disrupting CASP3, DAB2IP, DCLRE1C and
ITGA9 genes, respectively, were included in the study. Of
these CASP3 functions in apoptosis, failure of which can
lead to cancer [9]. DAB2IP encodes a member of the RAS
GTPase-activating gene family and has been reported to
act as a tumor suppressor: its inactivation by promoter
methylation occurs in several malignancies, including
prostate and breast cancer [10]. DCLRE1C operates in the
DNA double-strand break repair pathway, defect of which
has been strongly associated with breast cancer predispos-
ition [11], and ITGA9 encodes α-integrin, which partici-
pates in the control of cell division, differentiation and
migration [12-14]. The chromosomal region harboring
ITGA9 has been reported to be deleted in several epithe-
lial malignancies, including breast carcinoma [15].
Here we have defined the exact breakpoints of six previ-
ously identified deletion alleles disrupting the CYP2C19,
CDH19, CASP3, DCLRE1C, DAB2IP and ITGA9 genes,
respectively, and evaluated their association with breast
cancer risk and disease subtype using a Northern Finnish
case–control cohort. As a result, we provide evidence
suggestive of the CYP2C19 deletion allele being associ-




Patient cohort consisted of 842 Northern Finnish breast
cancer cases diagnosed at the Oulu University Hospital
between the years 2000 and 2011. All cases were unse-
lected for a family history of the disease and age at
disease onset. The median age at diagnosis for cases was
57 years (variation 28–92 years). 497 geographicallymatched anonymous cancer-free female Northern Finnish
Red-Cross blood donors (median age at monitoring was
42 years, variation 18–66 years) were used as controls.
Control samples were provided by Finnish Red Cross
Blood Service, with the information only about their gen-
der, age and place of blood donation. Controls have given
their informed consent to use part of their sample for re-
search purposes at the time of donation. The genomic
DNA of cases and controls was extracted from blood sam-
ples using either the standard phenol-chloroform method,
Puregene D-50 K purification kit (Gentra, Minneapolis,
MN, USA), or UltraClean Blood DNA Isolation Kit
(MoBio, Carlsbad, CA, USA)
For 551 of the breast cancer cases we had access to
the clinical parameters obtained from the pathology re-
ports. These included tumor histology, grade, size, nodal
status, distant metastases, estrogen receptor (ER), pro-
gesterone receptor (PR), HER2 and Ki-67 status. For ER
and PR, positive staining was defined as nuclear immuno-
staining in 1 to 10% (weak), 10 to 50% (moderate), or >50%
(strong) of the tumor cells, whereas negative indicated no
staining. HER2 expression was studied by means of immu-
nohistochemistry (positivity defined as weak, moderate or
strong levels of staining and negativity completely negative
staining) and chromogenic in situ hybridization (CISH).
Cut-off values used for Ki-67 were negative (0), weak (1),
moderate (2) and strong (3). ER, PR and HER2 status were
used as surrogate markers to divide the tumors further into
luminalA, luminalB, HER2 type and triple-negative sub-
types [16,17]. LuminalA was defined as positive ER or PR
expression and no HER2 overexpression, luminalB had
positive ER or PR and HER2 overexpression, HER2 type as
negative ER and PR but with HER2 overexpression, and
triple-negative as negative for all three markers.
All specimens and clinical information were collected
with the informed consent of the patients. This study was
approved by the Ethical Board of the Oulu University
Hospital Health Care District and the Finnish Ministry of
Social Affairs and Health.
Genotyping of the deletion alleles
The exact breakpoints of CYP2C19, CDH19, CASP3,
DCLRE1C, DAB2IP and ITGA9 genes disrupting deletion
CNVs were defined by performing qPCR (BioRad CFX96,
BioRad, Hercules, CA, USA) and nested PCR (GeneAmp
High Fidelity PCR System, Applied Biosystems, Foster City,
CA, USA) with the primers surrounding the breakpoint
coordinates received from Illumina HumanOmni1-Quad
BeadChips, analyzed with GenomeStudio Genotyping
module (Illumina Inc., San Diego, CA, USA) and Nexus
Copy Number Discovery Edition 5.1 software (BioDis-
covery Inc. El Segundo, CA, USA) [4]. The breakpoints
were verified by direct sequencing (ABI3130xl Genetic
Analyzer, Applied Biosystems, Foster City, CA, USA).
Tervasmäki et al. BMC Cancer 2014, 14:902 Page 3 of 7
http://www.biomedcentral.com/1471-2407/14/902Nested allele-specific PCR for the detection of the dele-
tion alleles was designed in a multiplex format, contain-
ing control primers to monitor PCR success. Deletion
CNV containing samples were used as positive controls.
Primers to amplify the deletion alleles are presented in
Additional file 1: Table S1. The obtained PCR amplicons
were analyzed with Bioanalyzer (Agilent Technologies,
Waldbronn, Germany). All the observed deletion carrier
samples were verified by direct sequencing. The hetero-
zygosity of the CYP2C19 and CDH19 deletion alleles
was confirmed by second, wild type allele specific PCR.
For CYP2C19, the same forward primer as in multiplex
reaction was used, reverse (ACTTGACGATGGAGGG
TGAA) resided on genomic region present only in wild
type allele. For CDH19, the reverse primer was the same
as in multiplex reaction, whereas the forward primer
(TCTGAATCTGGTGAGGGAACA) was wild type specific.
Genotyping for other CYP2C19 metabolizer alleles in
CYP2C19 deletion carriers
The status of the remaining CYP2C19 allele both in car-
riers with breast cancer and those remaining healthy
was investigated by genotyping for the three literature
described metabolizer types: CYP2C19*2 (c.681G > A,
rs4244285, poor metabolizer), CYP2C19*3 (c.636G > A,
rs57081121, poor metabolizer) and CYP2C19*17 (-806C >T,
rs12248560, ultra-rapid metabolizer) [18-21]. Genotyp-
ing was performed with direct sequencing (ABI3130xl
Genetic Analyzer) using primers in Additional file 1:
Table S2 [22-24].
Statistical analysis
Statistical analyses were performed with IBM SPSS Statis-
tics 20 (IBM Corporation, Armonk, NY, USA). P-values
for comparisons between cases and controls and for the
evaluation of the differences in tumor characteristics were
obtained using Pearson’s chi-squared or Fisher’s exact test.
Fisher’s exact test was used if any of the crosstab cells had
expected count less than 5. P-values were not corrected
for multiple testing in order not to eliminate potentially
significant findings obtained with small number of CNV
carriers. All p-values were two-sided.Table 1 Genomic coordinates, sizes and carrier frequencies of
Disrupted gene Location of deletion Deletion size
DCLRE1C Chr10: 14,983,925–15,065,676 82 kb
CASP3 Chr4: 185,506,876–185,841,468 335 kb
DAB2IP Chr9: 124,201,774–124,361,084 159 kb
ITGA9 Chr3: 37,750,166–37,810,925 61 kb
CDH19 Chr18: 64,082,045–64,335,669 254 kb
CYP2C19 Chr10: 96,497,324–96,559,110 62 kb
NA = not available, OR = odds ratio, CI = confidence interval. Genomic coordinates aResults
The exact coordinates for the deletion alleles corre-
sponded well to that received from microarrays [4], except
for DAB2IP, for which the deletion was significantly larger
than originally predicted (Additional file 1: Table S3). The
sequencing verified genomic coordinates of the deletions
and the carrier frequencies in the analyzed cohorts are
presented in Table 1. When performing case–control
comparisons, no additional CASP3, DCLRE1C or DAB2IP
deletion allele carriers were observed, indicating that these
alleles are either truly singletons or extremely rare. In con-
trast, ITGA9 deletion allele carriers were observed once in
cases and once in controls, leaving its potential role in
breast cancer predisposition uncertain. Of the two recur-
rent alleles, the CDH19 deletion showed higher frequency
in cases (12/842, 1.4%) than in controls (3/497, 0.6%), but
because of its rarity the difference remained below the
level of statistical significance (p = 0.168). The CYP2C19
deletion carrier frequency was only marginally higher in
the breast cancer cases (31/842, 3.7%) when compared to
the controls (17/497, 3.4%), being relatively high in both
groups (sequence of the CYP2C19 deletion breakpoints
and its surrounding area is presented in Additional file 2:
Figure S1). All CDH19 and CYP2C19 mutation positive
individuals were verified to be heterozygotes.
The case–control comparisons were followed by case-
case analysis for the differences in clinical parameters
between CNV carriers and non-carriers. The tumor char-
acteristics of CDH19 deletion carriers did not significantly
differ from non-carrier cases, although the carrier tumors
tended to be more frequently of higher grade (7/12,
58.3%, of the tumors categorized as grade 3) than the
non-carrier tumors (197/522, 37.7%) (Additional file 1:
Table S4). In contrast, for CYP2C19 the tumors of
deletion carriers showed association with negative ER
(p = 0.048) and PR status (p = 0.078), the latter, however,
remaining slightly below the level of statistical signifi-
cance. HER2 negativity was at similar level as in wild
type tumors (Table 2). When combining all three parame-
ters, CYP2C19 deletion carriers were at significantly higher
risk for developing triple-negative (ER/PR/HER2 negative)
tumors than non-carriers (p = 0.021, OR 2.83; 95% CI 1.20-the studied deletion alleles
Carrier frequency, n/N (%) P-value OR (95% CI)
Breast cancer cases controls
0/842 (−) 0/497 (−) NA NA
0/842 (−) 0/497 (−) NA NA
0/842 (−) 0/497 (−) NA NA
1/842 (0.1%) 1/497 (0.2%) 1.000 0.590 (0.037 – 9.450)
12/842 (1.4%) 3/497 (0.6%) 0.168 2.381 (0.669 – 8.478)
31/842 (3.7%) 17/497 (3.4%) 0.804 1.079 (0.591 – 1.971)
ccording to human genome assembly 19 (February 2009).
Table 2 Tumor characteristics of CYP2C19 deletion allele carriers compared with the tumors of non-carrier unselected
breast cancer cases
Category CYP2C19 deletion % Wild type % P-valuea OR 95% CI
T
1 18 62.0% 304 58.3%
2 10 34.5% 188 36.1% 0.692 1.17 0.54-2.52
3 1 3.5% 16 3.1% 1 vs. 2,3,4
4 0 0% 13 2.5%
N
Neg 20 64.5% 293 56.0% 0.354 1.43 0.67-3.04
Pos 11 35.5% 230 44.0%
M
Neg 31 100% 500 95.6% 0.632 NA
Pos 0 23 4.4%
ER
Neg 10 34.5% 101 19.3% 0.048 2.19 0.99-4.86
Pos 19 65.5% 421 80.7%
PR
Neg 13 44.8% 153 29.4% 0.078 1.95 0.92-4.16
Pos 16 55.2% 368 70.6%
HER2
Neg 24 82.8% 447 85.6% 0.595 0.81 0.30-2.18
Pos 5 17.2% 75 14.4%
Grade
1 4 12.9% 86 17.1%
2 14 45.2% 226 44.9% 0.659 0.85 0.41-1.77
3 13 41.9% 191 38.0% 1 and 2 vs. 3
Tumor histology
Ductal 23 79.2% 395 75.7%
Lobular 3 10.4% 90 17.2% 0.656 1.23 0.49-3.09
Medullary 0 0% 2 0.4% Ductal vs. all other
Other 3 10.4% 35 6.7%
Type
LumA 16 55.2% 385 73.8%
LumB 3 10.3% 43 8.2% 0.021 2.83 1.20-6.66
HER2 2 6.9% 32 6.1% Triple-neg vs. other
Triple-neg 8 27.6% 62 11.9%
Ki67
0 1 3.6% 71 13.7%
1 13 46.4% 231 44.5% 0.393 0.72 0.34-1.54
2 7 25.0% 112 21.6% 0 and 1 vs. 2 and 3
3 7 25.0% 105 20.2%
T = tumor size, N = nodal status, M = primary metastasis, ER = estrogen receptor, PR = progesterone receptor, LumA = luminalA, LumB = luminalB,
Neg = negative, Pos = positive.
anot corrected for multiple testing.
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characteristics of CYP2C19 deletion carriers are related to
estrogen responsiveness. As the known biological function
of CYP2C19 is related to estrogen catabolism, and as the
studied deletion allele is expected to be a null allele, we fur-
ther defined the status of the remaining CYP2C19 allele in
relation to literature described metabolizer genotypes both
in carriers with breast cancer and those remaining healthy.
No CYP2C19*3 poor metabolizers were identified, whereas
four CYP2C19*2 poor metabolizers were identified in
patients (4/31, 12.9%) and one in controls (1/17, 5.9%).
There was no difference in the frequency of CYP2C19*17
ultra-rapid metabolizer genotypes (7/31, 22.6% in patients
vs. 3/17, 17.6% in healthy controls), indicating that the
disease risk of individual with CYP2C19 deletion was
not significantly affected by the metabolizer status of
the remaining allele. Furthermore, in a majority (7/10) of
the deletion carriers with ER negative cancer the second
allele was found to be wild type, whereas one (1/10) had a
poor-metabolizer CYP2C19*2 allele and the rest (2/10) an
ultra-rapid metabolizer CYP2C19*17 allele.
Discussion
Inherited genomic alterations are expected to have an ef-
fect on individual’s risk of getting cancer. However, these
alterations may affect not only the risk but also the pattern
of somatically acquired mutations and thereby tumor biol-
ogy. Much of the work in this field has been concentrating
on single nucleotide polymorphisms (SNPs) whereas the
role of CNVs has remained poorly defined, partially
because their detection with Sanger or even with sophisti-
cated Next-Generation sequencing is hard or even impos-
sible, and the fast and cost-efficient investigation of CNV
alleles requires the characterization of their breakpoints in
exact detail. Of the currently studied rare CNV alleles, the
breakpoints of five out of six were adequately well de-
scribed by the used analysis software, indicating that high-
resolution microarrays can predict fairly well the genuine
genomic coordinates of the aberrations. The singleton
CNVs previously identified in familial or early-onset cases
[4] were absent from, or remained extremely rare in the
unselected breast cancer cases, but the two recurrent
alleles were observed at higher frequency. The carrier fre-
quency of the CDH19 deletion was twice as high in unse-
lected breast cancer cases as in controls but remained
below statistical significance, indicating the need for larger
case–control cohorts to demonstrate its association with
breast cancer. The other recurrent CNV allele, CYP2C19
deletion, had surprisingly high prevalence both in the
studied cases and controls (>3%), particularly when con-
sidering that deletion CNVs have rarely been reported
in CYP genes, despite the numerous studies performed.
This can be explained by the poor detection of CNV al-
leles by conventional genotyping methods, but also bythe fact that our study was performed with samples
from Finnish founder population. Founder populations
are known to harbor unique mutations and some of the
mutations rare in other populations can also show enrich-
ment in them. In regard to cancer predisposition, the ef-
fect of the CYP2C19 deletion was reminiscent to that of a
low-penetrance allele. However, it was found to be associ-
ated specifically with the triple-negative molecular subtype
of the breast cancer.
There are multiple lines of evidence for the profound
role of estrogen in breast cancer development: disrup-
tions in estrogen signalling and metabolism have long
been considered to affect breast cancer risk. This can
result from different reproductive and hormonal factors
[25], but could also be due to variations in the enzymatic
machinery responsible for estrogen metabolism. Indeed,
the currently studied CYP2C19 deletion CNV is expected
to result in a null allele of a gene encoding an enzyme in-
volved in estrogen catabolism [5,6]. All currently identified
mutation positive individuals were heterozygous for the
CYP2C19 deletion, and the genotype of the remaining al-
lele seemed not to play a role in the observed association
with tumor triple-negativity. This could be explained by a
genuine haploinsufficient situation, in which single allele is
unable to sustain full functionality when compared to the
protein levels produced by two wild type alleles. Alterna-
tively, as the CYP2C19 deletion allele extends over 60 kb,
starting only 1377 bp from the 3’ end of the adjacent
CYP2C18 gene, it could change the genomic landscape of
this region in a way that leads to aberrant expression of
both genes. It is also possible that large genomic deletions
disturb the communication between the homologous al-
leles required for their full function by deleting regulatory
elements required for this process [26].
Another CYP2C19 allele, CYP2C19*17, defining an ultra-
rapid metabolizer phenotype, has previously been associ-
ated with a decreased risk for breast cancer. This suggests
that increased catabolism of estrogens by CYP2C19 may
lead to decreased estrogen levels and therefore reduced
breast cancer risk [27]. Correspondingly, our initial hypoth-
esis was that CYP2C19 deletion allele effects are mediated
through life-long increased estrogen levels. Why this would
predispose particularly to ER negative breast cancer is
currently, however, puzzling and the mechanism through
which the CYP2C19 deletion operates remains unclear.
However, any perturbations in estrogen metabolism are
still among the possible explanations. Curiously, there are
also reports linking obesity with triple-negative breast
cancer [28]. Although obesity-related insulin resistance
and chronic inflammatory could be possible explana-
tions for this phenomenon, increased body mass index
is known to cause changes in the hormonal cycles and
result in excessive adipose tissue [29,30]. This can in-
crease the estrogen production and availability, leading
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breast cancer. Nevertheless, as triple-negative breast can-
cer is a tumor subtype with unique characteristics not
only in its pathological presentation but also in prognosis
and response to therapy, identification of additional risk
factors specifically associated with this subgroup of breast
cancer could help to understand its etiology.
Conclusion
Our results indicate that an inherited defect in the
CYP2C19 gene with a role in estrogen catabolism has an
influence on the molecular subtype of breast cancer and is
significantly associated with triple-negative tumors. The
role of the CYP2C19 deletion allele, as well as that of the
CDH19 deletion, in breast cancer predisposition warrants
further studies and the obtained results should be repli-
cated with larger and independent case–control cohorts.
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